• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current Eye Research >Comparative in vitro toxicology study of travoprost polyquad-preserved, travoprost BAK-preserved, and latanoprost BAK-preserved ophthalmic solutions on human conjunctival epithelial cells.
【24h】

Comparative in vitro toxicology study of travoprost polyquad-preserved, travoprost BAK-preserved, and latanoprost BAK-preserved ophthalmic solutions on human conjunctival epithelial cells.

机译：travoprost保鲜剂，travoprost BAK保鲜剂和latanoprost BAK保鲜剂对人结膜上皮细胞的体外毒理学比较研究。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE: To compare the toxicological profile of a new formulation of travoprost 0.004% ophthalmic solution (travoprost PQ), containing the preservative polyquaternium-1(PQ, polyquad), with the commercially available formulation of benzalkonium chloride (BAK)-preserved travoprost 0.004% ophthalmic solution (travoprost BAK) and BAK-preserved latanoprost 0.005% ophthalmic solution (latanoprost BAK). MATERIALS AND METHODS: Human conjunctival epithelial cells were incubated with phosphate-buffered saline (PBS), BAK 0.015%, BAK 0.020%, PQ 0.001%, travoprost PQ preserved with PQ 0.001%, travoprost preserved with BAK 0.015%, or latanoprost preserved with BAK 0.020%. Six toxicological assays were used to assess: cell viability (neutral red, Alamar blue), apoptosis (YO-PRO-1, Hoechst 33342), and oxidative stress (H(2)DCF-DA, hydroethidine). Apoptosis and oxidative stress were each reported according to cell viability as observed with neutral red and Alamar blue for a total of 10 analyses per treatment depending on the cell viability test used to interpret apoptosis and oxidative stress responses. RESULTS: There were no significant differences in toxicity between cells exposed to PBS and cells exposed to travoprost PQ (10/10 analyses) or PQ 0.001% (9/10 analyses). Ten out of 10 analyses revealed that travoprost PQ produced significantly less cytotoxicity than latanoprost BAK (p < 0.0001). Travoprost PQ produced significantly better cell viability and less apoptosis than travoprost BAK (6/6 analyses, p < 0.0001). Travoprost BAK was significantly less cytotoxic than latanoprost BAK in 7 of 10 analyses (p < 0.0001). All 10 of the analyses revealed that BAK 0.015%, BAK 0.020%, and latanoprost BAK produced significantly more cytotoxicity than PBS (p < 0.0001). Travoprost BAK was significantly less cytotoxic than its corresponding BAK 0.015% preservative solution in 9 of 10 analyses (p < 0.0001). CONCLUSIONS: A panel of in vitro toxicity analyses supports the safety of travoprost PQ. Travoprost PQ may be better for ocular surface health than BAK-preserved formulations of latanoprost or travoprost but clinical studies are required to validate these comparisons.
机译：目的：为了比较含有防腐剂polyquaternium-1（PQ，polyquad）的新的travoprost 0.004％眼药水制剂（travoprost PQ）的毒理学特征与苯扎氯铵（BAK）保存的travoprost 0.004％的市售制剂的毒理学特征眼药水（travoprost BAK）和保存BAK的拉坦前列素0.005％眼药水（latanoprost BAK）。材料与方法：将人结膜上皮细胞与磷酸盐缓冲液（PBS），BAK 0.015％，BAK 0.020％，PQ 0.001％，travoprost PQ保留0.001％，travoprost保留BAK 0.015％或latanoprost一起孵育比克0.020％。六种毒理学分析用于评估：细胞活力（中性红，阿拉玛蓝），细胞凋亡（YO-PRO-1，Hoechst 33342）和氧化应激（H（2）DCF-DA，氢乙啶）。根据中性红和Alamar蓝观察到的细胞活力分别报告细胞凋亡和氧化应激，每种治疗总共进行10次分析，具体取决于用于解释凋亡和氧化应激反应的细胞活力测试。结果：暴露于PBS的细胞与暴露于travoprost PQ（10/10分析）或PQ 0.001％（9/10分析）的细胞之间的毒性没有显着差异。 10个分析中有10个显示travoprost PQ产生的细胞毒性明显低于latanoprost BAK（p <0.0001）。与travoprost BAK相比，Travoprost PQ产生的细胞活力明显更好，凋亡更少（6/6分析，p <0.0001）。在10项分析中的7项中，Travoprost BAK的细胞毒性明显低于latanoprost BAK（p <0.0001）。所有10项分析均显示，BAK 0.015％，BAK 0.020％和拉坦前列素BAK产生的细胞毒性明显高于PBS（p <0.0001）。在10个分析中的9个中，Travoprost BAK的细胞毒性明显低于其相应的BAK 0.015％防腐剂溶液（p <0.0001）。结论：一组体外毒性分析支持曲普前列素PQ的安全性。 Travoprost PQ对眼表健康可能比保存BAK的拉坦前列素或travoprost制剂更好，但需要临床研究来验证这些比较。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号